Lipid nanoparticle delivery of mRNA could lead to new ‘universal’ COVID-19 treatment
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
List view / Grid view
A study has shown that mRNA delivered via lipid nanoparticles blocks multiple variants of SARS-CoV-2 from entering cells in mice.
A potential Zika virus vaccine, developed by deleting part of the Zika genome that codes for the viral shell, was effective and safe in mice.
The best protection from COVID-19 will come from intranasally-delivered vaccines, due to the effectiveness of mucosal IgA antibodies, say researchers from the University at Buffalo.
The Scripps Research team showed that a variation of an already FDA-approved therapeutic for neurological disease can block COVID-19 infection in animals.
A recently discovered SARS-CoV-2 virus in a Russian bat is likely to be capable of infecting humans and resistant to current vaccines.
In the search for a rapid, easy way to identify drugs to fight SARS-CoV-2, researchers from across the US came together to develop and apply a high-throughput ADP-ribosylhydrolase assay, ADPr-Glo. Here, Dr Veronica Busa and Dr Anthony Leung from Johns Hopkins University describe the ADPr-Glo assay and how it can be…
Researchers have used a high-throughput assay to screen for potential small molecule SARS-CoV-2 replication inhibitors.
Antibody therapy has been a critical part of the COVID-19 research campaign to treat severe cases. Unfortunately, despite many promising candidates, scientists have yet to find one that passes clinical trials. This article by Drug Target Review’s Ria Kakkad highlights some of the most recent developments in the search for COVID-19…
Researchers screened biologically active small molecules, finding several compounds with the ability to induce training effects on macrophages.
Scientists have discovered antibodies that are effective against many different COVID-19 variants.
Researchers have designed a COVID-19 vaccine to be less sensitive to mutations and equipped for future strains.
Researchers have developed a needle-free mucosal bacteriophage (phage) T4-based COVID-19 vaccine is effective against SARS-CoV-2 infection.
The vaccine attaches spike proteins from SARS-CoV-2 and seven other SARS-like betacoronaviruses to a protein nanoparticle structure, to induce the production of a broad spectrum of cross-reactive antibodies.
The researchers used a modified live attenuated mumps virus for delivery, showing that a more stable coronavirus spike protein stimulates a stronger immune response, and suggesting a dose up the nose has an advantage over a shot.
Researchers have shown that a specific area of the SARS-CoV-2 spike protein is a promising target for a pan-coronavirus vaccine that could offer some protection against new virus variants, common colds, and help prepare for future pandemics.